Wentworth Alcohol Free

Sodium Fluoride


Sheffield Pharmaceuticals Llc
Human Prescription Drug
NDC 11527-735
Wentworth Alcohol Free also known as Sodium Fluoride is a human prescription drug labeled by 'Sheffield Pharmaceuticals Llc'. National Drug Code (NDC) number for Wentworth Alcohol Free is 11527-735. This drug is available in dosage form of Mouthwash. The names of the active, medicinal ingredients in Wentworth Alcohol Free drug includes Sodium Fluoride - .9 mg/mL . The currest status of Wentworth Alcohol Free drug is Active.

Drug Information:

Drug NDC: 11527-735
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Wentworth Alcohol Free
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Sodium Fluoride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Sheffield Pharmaceuticals Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Mouthwash
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:SODIUM FLUORIDE - .9 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:DENTAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 15 Apr, 2021
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Sheffield Pharmaceuticals LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:562510
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:8ZYQ1474W7
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
11527-735-161 BOTTLE, PLASTIC in 1 CARTON (11527-735-16) / 473 mL in 1 BOTTLE, PLASTIC15 Apr, 2021N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Wentworth alcohol free sodium fluoride sodium fluoride fluoride ion benzoic acid glycerin poloxamer 338 propylene glycol sodium benzoate water fd&c blue no. 1 a clear blue solution

Indications and Usage:

Indications and usage a dental caries preventive, for weekly self-applied topical use. weekly rinsing with a neutral 0.2% sodium fluoride solution protects against dental caries in adults and pediatric patients. wentworth sodium fluoride rinse provides a ready-to-use preparation for convenient administration and favorable compliance. may be used in areas where drinking water is fluoridated since topical fluoride cannot produce fluorosis. (see warnings for exception.)

Warnings:

Warnings keep out of reach of infants and children. pediatric patients under age 12 should be supervised in the use of this product. patients under age 6 require special supervision to prevent repeated swallowing of rinse since they frequently swallow significant amounts while rinsing. prolonged daily ingestion may result in dental fluorosis in patients under age 6, especially if the water fluoridation exceeds 0.6 ppm. read directions carefully before using. do not use if printed neck band is broken or missing

General Precautions:

General not for systemic treatment. do not swallow.

Dosage and Administration:

Dosage and administration for caries — adults and pediatric patients over age 6 years, 2 teaspoons (10 ml). once a week, preferably at bedtime after thoroughly brushing the teeth, rinse vigorously around and between the teeth for one minute, then expectorate. do not swallow. for maximum benefit, do not eat, drink, or rinse mouth for at least 30 minutes afterwards.

Contraindications:

Contraindiactions do not use in patients with dysphagia. do not use in pediatric patients under age 6 years unless recommended by a dentist or physician.

Adverse Reactions:

Adverse reactions in patients with mucositis, gingival tissues may be hypersensitive to flavor present in formulation. allergic reactions and other idiosyncrasies are rarely reported.

Use in Pregnancy:

Pregnancy teratogenic effects pregnancy category b it has been shown that fluoride crosses the placenta of rats, but only 0.01% of the amount administered is incorporated in fetal tissue. animal studies (rats, mice, rabbits) have shown that fluoride is not a teratogen. maternal exposure to 12.2 mg fluoride/kg of body weight (rats) or 13.1 mg/kg of body weight (rabbits) did not affect litter size or fetal weight and did not increase frequency of skeletal or visceral malformations. there are no adequate and well-controlled studies in pregnant women. however, epidemiological studies conducted in areas with high levels of naturally fluoridated water showed no increase in birth defects. heavy exposure to fluoride during in utero development may result in skeletal fluorosis which becomes evident in childhood.

Pediatric Use:

Pediatric use the use of wentworth ® sodium fluoride rinse as a weekly caries preventive in pediatric patients aged 6 to 16 years is supported by adequate and well-controlled clinical studies in students aged 6 to 12 years. 1-4 safety and effectiveness in pediatric patients below the age of 6 years have not been established. please refer to the contraindications and warnings sections.

Geriatric Use:

Geriatric use of the total number of subjects in clinical studies of 1.1% (w/v) sodium fluoride, 15 percent were 65 and over, while 1 percent were 75 and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Overdosage:

Overdosage accidental ingestion of large amounts of fluoride may result in acute burning in the mouth and sore tongue. nausea, vomiting, and diarrhea may occur soon after ingestion (within 30 minutes) and are accompanied by salivation, hematemesis, and epigastric cramping abdominal pain. these symptoms may persist for 24 hours. if less than 5 mg fluoride/kg body weight (i.e., less than 2.3 mg fluoride/lb body weight) has been ingested, give calcium (e.g., milk) orally to relieve gastrointestinal symptoms and observe for a few hours. if more than 5 mg fluoride/kg body weight (i.e., more than 2.3 mg fluoride/lb body weight) has been ingested, induce vomiting, give orally soluble calcium (e.g., milk, 5% calcium gluconate or calcium lactate solution) and immediately seek medical assistance. for accidental ingestion of more than 15 mg fluoride/kg of body weight (i.e., more than 6.9 mg fluoride/lb body weight), induce vomiting and admit immediately to a hospital facility. a treatment dose (10 ml or two teaspoonfuls) of wentworth ® sodium fluoride rinse contains approximately 9 mg fluoride. one 16 fl. oz. bottle contains approximately 429 mg fluoride.

Description:

Description wentworth sodium fluoride rinse 0.2% of neutral sodium fluoride is a mint-flavored, neutral, aqueous solution. active ingredient sodium fluoride 0.2% (w/v) inactive ingredients benzoic acid, flavor, glycerin, poloxamer 338, propylene glycol, sodium benzoate, water, fd&c blue no. 1

Clinical Pharmacology:

Clinical pharmacology topical application of sodium fluoride increases tooth resistance to acid dissolution, promotes remineralization, and inhibits the cariogenic microbial process.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility no carcinogenesis was found in mice or female rats treated with fluoride at doses ranging from 4.1 to 9.1 mg/kg of body weight. equivocal evidence of carcinogenesis was reported in male rats treated with 2.5 and 4.1 mg/kg of body weight. in another study, no carcinogenesis was observed in rats treated with fluoride up to 11.3 mg/kg of body weight. epidemiological data provide no credible evidence for an association between fluoride, either naturally occurring or added to drinking water, and risk of human cancer. fluoride ion is not mutagenic in standard bacterial systems but has been associated with chromosome aberrations in cultured human and rodent cells at doses much higher than expected human exposures. some in vivo report chromosome damage in rodents while other studies using similar protocols report negative results. potential adverse reproductive effects of fluoride exposure in humans has not been adequately evaluated. adverse
effects on reproduction were reported for rats, mice, fox, and cattle exposed to 100 ppm or greater concentrations of fluoride in their diet or drinking water. other studies conducted in rats demonstrated that lower concentrations of fluoride (5 mg/kg of body weight) did not result in impaired fertility and reproductive capabilities.

How Supplied:

How supplied plastic bottle with child-resistant closure containing 16 fl. oz. (473 ml) (ndc 11527-735-16). storage store at controlled room temperature, 68-77°f (20-25°c).

Package Label Principal Display Panel:

Principal display panel - 473 ml rinse label ndc 11527-735-16 wentworth ® alcohol free sodium fluoride rinse 0.2% neutral sodium fluoride reduces cari es up to 55% 1 cool mint keep out of reach of infants and children 16 fl oz (1 pt) 473 ml rx only wentworth sodium fluoride rinse label.jpg

Principal display panel - 473 ml carton label ndc 11527-735-16 wentworth ® alcohol free sodium fluoride rinse 0.2% neutral sodium fluoride reduces cari es up to 55% 1 cool mint keep out of reach of infants and children 16 fl oz (1 pt) 473 ml rx only wentworth sodium fluoride rinse carton.jpg


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.